Bafna Pharmaceuticals Limited

NSE BAFNAPH.NS

Bafna Pharmaceuticals Limited Price to Earnings Ratio (P/E) on February 07, 2025: 24.65

Bafna Pharmaceuticals Limited Price to Earnings Ratio (P/E) is 24.65 on February 07, 2025, a 13.60% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Bafna Pharmaceuticals Limited 52-week high Price to Earnings Ratio (P/E) is 37.24 on May 06, 2024, which is 51.09% above the current Price to Earnings Ratio (P/E).
Bafna Pharmaceuticals Limited 52-week low Price to Earnings Ratio (P/E) is 16.97 on March 27, 2024, which is -31.16% below the current Price to Earnings Ratio (P/E).
Bafna Pharmaceuticals Limited average Price to Earnings Ratio (P/E) for the last 52 weeks is 26.33.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NSE: BAFNAPH.NS

Bafna Pharmaceuticals Limited

CEO	Mr. Bansilal Mahaveer Chand Bafna
IPO Date	Nov. 12, 2012
Location	India
Headquarters	Bafna Towers
Employees	363
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Cleaning Supplies Composite Materials Cosmetics Drugstores & Retail Pharmacies Glass Plastics

Description

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.

Key trends

Past 5 years